NRSN (NeuroSense Therapeutics) Revenue: $0.00 Mil (TTM As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.72
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Revenue?

NeuroSense Therapeutics NRSN +1.42% 31 Revenue is $0.00 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's revenue for the six months ended in Dec. 2025 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. NeuroSense Therapeutics's Revenue per Share for the six months ended in Dec. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

NeuroSense Therapeutics  (NAS:NRSN) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

NeuroSense Therapeutics Revenue Related Terms

NeuroSense Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Revenue Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NRSN vs SER, PVCT, IGC: Revenue Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Revenue falls into.


NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
NeuroSense Therapeutics (NRSN) has a Revenue of $0.00 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Revenue too high?
NeuroSense Therapeutics' current Revenue is $0.00 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Revenue compare to SER and PVCT?
NeuroSense Therapeutics' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Revenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price